NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Snyder DL, Sullivan N, Schoelles KM. Skin Substitutes for Treating Chronic Wounds [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Dec 18.
This publication is provided for historical reference only and the information may be out of date.
Table 13Results for complete wound healing
| Study | Wound Type | Skin Substitute | Comparison | Number of Patients in Study | Difference in Rate of Wounds Healed (Skin Substitute – Comparator) | p-Valuea | Relative Risk for Complete Wound Healing (95% CI) for Skin Substitute vs. Comparatora |
|---|---|---|---|---|---|---|---|
| DiDomenico et al. 201164 | DFU | Apligraf | TheraSkin | 28 | Healed at 12 weeks 41% - 67% = -26% | NS (p=0.21) | 0.66 (0.33 to 1.30) |
| Landsman et al. 200854 | DFU | Oasis Wound Matrix | Dermagraft | 26 | Healed at 12 weeks 77% - 85% = -8% | NS (p=0.62) | 0.91 (0.62 to 1.33) |
| Reyzelman et al. 200966 | DFU | Graftjacket acellular matrix | Moist wound therapy with alginates, foams, hydrocolloids, or hydrogels | 85 | Healed at 12 weeks 70% - 46% = 24% | 0.03 | 1.51 (1.02 to 2.22) |
| Brigido 200659 | DFU | Graftjacket acellular matrix | Weekly debridement, Curasol wound hydrogel and gauze dressing | 28 | Healed at 12 weeks 57% - 7% = 50% | 0.001 | 8.00 (1.15 to 55.80) |
| Niezgoda et al. 200570 | DFU | Oasis Wound Matrix | Regranex Gel (contains platelet-derived growth factor) | 98 | Healed at 12 weeks 49% - 28% = 21% | NS (p=0.06) | 1.75 (0.94 to 3.26) |
| Edmonds 200953 | DFU | Apligraf | Nonadherent dressing | 72 | Healed at 12 weeks 52% - 26% = 26% | 0.03 | 1.96 (1.05 to 3.66) |
| Marston et al. 200356 | DFU | Dermagraft | Saline-moistened gauze | 245 | Healed at 12 weeks 30% - 18% = 12% | 0.03 | 1.64 (1.03 to 2.62) |
| Naughton et al. 199762 | DFU | Dermagraft | Saline-moistened gauze | 109 | Healed at 12 weeks 39% - 32% = 7% | NS (p=0.28) | 1.21 (0.86 to 1.72) |
| Gentzkow et al. 199665 | DFU | Dermagraft | Saline-moistened gauze | 50 | Healed at 12 weeksb 30% - 8% = 22% | 0.04 | 1.93 (0.49 to 7.59) |
| Veves et al. 200167 | DFU | Graftskin | Saline-moistened gauze | 208 | Healed at 12 weeks 56% - 38% = 18% | 0.01 | 1.50 (1.11 to 2.04) |
| Uccioli et al. 201168 | DFU | Hyalograft 3D autograft/Lasers Skin | Nonadherent paraffin gauze | 160 | Healed at 12 weeks 24% - 21% = 3% | NS (p=0.64) | 1.15 (0.64 to 2.04) |
| Caravaggi et al. 200358 | DFU | Hyalograft 3D autograft/LaserSkin | Nonadherent paraffin gauze | 79 | Healed at 11 weeks 65% - 50% = 15% | NS (p=0.17) | 1.30 (0.88 to 1.93) |
| Falanga et al. 199863 | Leg, Venous | Apligraf and elastic compression bandage | Compression therapy with a Unna boot and elastic compression bandage | 275 | Healed at 12 weeksc 53% - 22% = 31% | <0.001a | 2.38 (1.67 to 3.39) |
| Krishnamoorthy et al. 200355 | Leg, Venous | Dermagraft plus multilayered compression bandage therapy (Profore™) | Multilayered compression therapy | 52 | Healed at 12 weeks 28% - 15% = 13%c | NS (p=0.30)c | 1.83 (0.47 to 7.21)c |
| Romanelli et al. 201057 | Leg, Mixed | Oasis Wound Matrix | Petrolatum-impregnated gauze | 48 | Healed at 8 weeksd 80% - 65% = 15% | NS (p=0.25)d | 1.23 (0.86 to 1.75) |
| Romanelli et al. 200760 | Leg, Mixed | Oasis Wound Matrix | Hyaloskin (contains hyaluronan) | 54 | Healed at 16 weeks 83% - 46% = 37% | 0.001 | 1.91 (1.16to 3.14) |
| Mostow et al. 200569 | Leg, Venous | Oasis Wound Matrix with compression | Compression alone | 120 | Healed at 12 weeks 55% - 34% = 21% | 0.022 | 1.59 (1.04 to 2.42) |
| Kelechi et al. 201161 | Leg, Venous | Talymed poly-N-acetyl glucosamine (pGlcNAc) with compression | Nonadherent absorptive primary dressing with compression | 82 | Healed at 20 weekse 66% - 45% = 21% | NS (p=0.10) | 1.47 (0.88 to 2.46)e |
DFU: Diabetic foot ulcer
HYAFF: Benzyl esters of hyaluronic acid
Leg: Vascular leg ulcer
NS: Not Statistically Significant
- a
Calculated by ECRI Institute; p values are for Risk Difference
- b
Calculated for all three active groups combined vs. control. A dose-response was noted with more frequent application of Dermagraft associated with higher percentage of patients with complete wound healing.
- c
Complete healing at 12 weeks calculated from Figure 1 C in Brigido (2006) and from Table 2 and Figure 5 in Falanga (1998)
- d
The publication states that the p-value for this comparison was “P<0.05”; however we calculate a risk difference of 0.15 (-0.10 to 0.40), p=0.25, a nonsignificant result. The authors state that they used “analysis of variance for multiple comparisons,” but no variables by which the data might have been adjusted are discussed.
- e
All 3 Talymed groups combined vs. placebo; for groups receiving Talymed every other week to every third week vs. control, the difference was significant at the p=0.016 level, and the relative risk was 1.69 (1.01 to 2.83).
- Table 13, Results for complete wound healing - Skin Substitutes for Treating Chr...Table 13, Results for complete wound healing - Skin Substitutes for Treating Chronic Wounds
Your browsing activity is empty.
Activity recording is turned off.
See more...